MARKET

FATE

FATE

Fate
NASDAQ

Real-time Quotes | Nasdaq Last Sale

82.80
-3.24
-3.77%
After Hours: 82.80 0 0.00% 16:00 07/30 EDT
OPEN
85.42
PREV CLOSE
86.04
HIGH
86.91
LOW
82.35
VOLUME
414.94K
TURNOVER
--
52 WEEK HIGH
121.16
52 WEEK LOW
29.37
MARKET CAP
7.79B
P/E (TTM)
-39.0621
1D
5D
1M
3M
1Y
5Y
Earnings Preview: Fate Therapeutics (FATE) Q2 Earnings Expected to Decline
Zacks.com · 2d ago
Fate Therapeutics Inc (FATE) President and CEO J Scott Wolchko Sold $5.1 million of Shares
GuruFocus News · 3d ago
SevenBridge Financial Group, LLC Buys Invitae Corp, Fate Therapeutics Inc, Intel Corp, Sells ...
GuruFocus News · 4d ago
Dowling & Yahnke Llc Buys Vanguard S&P 500 ETF, Fate Therapeutics Inc, MicroStrategy ...
GuruFocus News · 07/21 16:38
Cathie Wood's ARK Invest Posts Fund Purchases For Thursday, July 15, 2021: RPTX, VERV, FATE, SGFY, QSI, COIN, EXAS, U, KTOS, MKFG, PATH, CND, KVSB
Repare Therapeutics (RPTX) - 39,887 Shares Verve Therapeutics (VERV) - 60,256 Fate Therapeutics (FATE) - 152,712 Signify Health (SGFY) - 36,732 Quantum-Si (QSI) - 347,305 Coinbase Global (COIN) - 69,172 Exact
Benzinga · 07/16 14:27
Fate Therapeutics Highlights Will Host Virtual Event On Interim Phase 1 Trial Data From Its Off-The-Shelf NK Cell Franchise For B-Cell Lymphoma
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that management will host a virtual event
Benzinga · 07/16 12:04
Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma
SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that management will host a virt...
GlobeNewswire · 07/16 12:00
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results
SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will host a con...
GlobeNewswire · 07/15 20:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FATE. Analyze the recent business situations of Fate through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FATE stock price target is 111.71 with a high estimate of 145.00 and a low estimate of 71.00.
EPS
Institutional Holdings
Institutions: 315
Institutional Holdings: 99.08M
% Owned: 105.37%
Shares Outstanding: 94.04M
TypeInstitutionsShares
Increased
89
11.08M
New
50
1.33M
Decreased
88
4.46M
Sold Out
37
632.96K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.26%
Pharmaceuticals & Medical Research
-0.35%
Key Executives
Non-Executive Chairman/Independent Director
William Rastetter
President/Chief Executive Officer/Director
John Wolchko
Non-Executive Vice Chairman/Independent Director
John Mendlein
Chief Financial Officer
Edward Dulac
Senior Vice President
Yu-Waye Chu
Chief Technology Officer
Mark Plavsic
General Counsel/Secretary
Cindy Tahl
Other
Bahram Valamehr
Independent Director
Shefali Agarwal
Independent Director
Timothy Coughlin
Independent Director
Robert Epstein
Independent Director
Robert Hershberg
Independent Director
Karin Jooss
Independent Director
Michael Lee
No Data
  • All
  • Financials
  • Insiders
More
About FATE
Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

Webull offers kinds of Fate Therapeutics Inc stock information, including NASDAQ:FATE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FATE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FATE stock methods without spending real money on the virtual paper trading platform.